权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Intracellular Trafficking of DNA for Gene Therapy

用于基因治疗的 DNA 细胞内运输

基本信息

批准号：
10710840
负责人：
David A Dean
金额：
$ 39.81万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10710840
关键词：
Affect Affinity Animals Architecture Binding Binding Sites CREB1 gene Cell Nucleolus Cell Nucleus Cell division Cell membrane Cells Complex Cytoplasm Cytoskeleton DNA DNA Binding DNA Binding Domain DNA Polymerase I DNA Polymerase II DNA Polymerase III DNA Sequence DNA cassette DNA delivery Disease Gene Delivery Gene Expression Gene Order Gene Transfer Genes Genetic Materials Genetic Transcription Goals Host Defense Immune response Importins In Vitro Inflammation Inflammatory Inflammatory Response Innate Immune System Interferons Interphase Cell Laboratories Mediating Messenger RNA Methods Microtubules Motor Movement NF-kappa B NFIA gene Normal Statistical Distribution Nuclear Nuclear Envelope Nuclear Import Nuclear Localization Signal Pathway interactions Patients Plasmids Polymerase Production Proteins RNA Polymerase II RNA Splicing Receptor Signaling Ribosomal RNA Signal Transduction Site Stimulator of Interferon Genes Time Tissues Transfection Travel Viral Work cytokine defense response ds-DNA effective therapy gene therapy improved in vivo mechanical force plasmid DNA promoter release factor residence sensor small hairpin RNA therapeutic gene trafficking transcription factor transgene expression

项目摘要

Under almost all conditions using any method, the levels of gene transfer to any cell or tissue are low because many barriers exist for the efficient delivery of genes to cells. The primary goal of our laboratory is to identify and overcome the intracellular barriers to promote effective gene delivery and therapy. Exogenous viral or non- viral DNA must cross the plasma membrane, travel through the cytoplasm and the cytoskeletal networks, cross the nuclear envelope, localize to specific regions within the nucleus, and be transcribed in order for gene therapy to be successful. We have shown that once in the cytoplasm, plasmids carrying DNA nuclear targeting sequences (DTS) that are required for nuclear import in non-dividing cells rapidly associate with transcription factors that mediate movement along microtubules and across the nuclear envelope. NF-kB is one such factor that binds to several ubiquitously active DTSs and is required for DNA nuclear import, but in the cytoplasm it is maintained in a sequestered state, unable to bind DNA. The question then is how is NF-kB activated to bind to plasmids and mediate their cytoskeletal movement and nuclear import? In the case of NF-kB, a major pathway for its activation is through a set of cytoplasmic dsDNA sensors, such as cGAS-STING, that are part of the innate immune system and drive inflammatory responses. When dsDNA binds to cGAS, signaling cascades are initiated that result in activation of key pro-inflammatory transcription factors (including NF-kB) and ultimately production of pro-inflammatory cytokines. Thus, a major focus in the gene therapy space has been to block activation of these sensors to reduce inflammation. However, we have observed that when cGAS is silenced, cytoplasmically injected plasmids fail to traffic to the nucleus. We hypothesize that limited activation of one or more of these sensors is actually needed for low level activation of key transcription factors in order to facilitate DNA nuclear import in non-dividing cells. If we can find ways to limit sensor activation, but not abolish it, this will allow for enhanced gene delivery with limited accompanying inflammation. We have also spent considerable effort detailing the distribution of plasmids inside the nucleus and have found that the subnuclear mislocalization of plasmids can affect their transcriptional activity. We have found that plasmids localize to discrete transcriptional domains within the nucleus based on the type of promoter (Pol I, Pol II, or Pol III) they carry and that when two different promoter types are placed on one plasmid, not only is the intranuclear distribution of the DNA different that either promoter type alone, but transgene expression is significantly reduced. We will dissect the pathways used for DNA movement within the nucleus and exploit them to improve transgene expression based on the subnuclear localization of the transfected DNA. Our specific aims are to (1) determine whether cytosolic dsDNA sensors are required for DNA nuclear import; (2) evaluate whether residence time of DNA in the cytoplasm affects sensor activation and transfection efficiency; and (3) characterize how subnuclear organization affects exogenous DNA expression.

在几乎所有条件下使用任何方法，基因转移到任何细胞或组织的水平都很低，因为